SonALAsense

About SonALAsense

SonALAsense is dedicated to transforming cancer patients into cancer survivors by developing sonodynamic therapy (SDT), a noninvasive treatment combining a tumor-targeting drug (SONALA-001) with an ultrasound device. Their mission is to provide hope and effective cancer treatments.

Products & Services

SONALA-001:A tumor-targeting drug used in combination with an ultrasound device as part of sonodynamic therapy (SDT) to treat cancer noninvasively.

Sonodynamic Therapy (SDT):A platform technology that metabolically targets cancer cells to cause immediate and programmed cell death, currently in clinical trials for brain tumors and blood cancers.

Specialties

Sonodynamic Therapy (SDT) Cancer Treatment Noninvasive Medical Technology Brain Tumor Treatment Blood Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 46000000 MR: - FA: up to $46 million FAN: 46000000	D: 2024-12-13 FD: 2024-12-13	1 investors

Grant Latest

2024-12-13

$46.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stuart Marcus

Founder and CSO

M

Mark de Souza

President and CEO

N

Nandini Kandolha

CFO

J

Joanne LaValle

Consultant, Regulatory Affairs

B

Brian Roden

CMC Advisor

B

Brian Rogers

Non-Clinical Advisor

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

SonALAsense Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised